These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2655606)

  • 1. Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study.
    Furst DE; Clements PJ; Hillis S; Lachenbruch PA; Miller BL; Sterz MG; Paulus HE
    Arthritis Rheum; 1989 May; 32(5):584-93. PubMed ID: 2655606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The course of skin involvement in systemic sclerosis over three years in a trial of chlorambucil versus placebo.
    Clements P; Lachenbruch P; Furst D; Paulus H
    Arthritis Rheum; 1993 Nov; 36(11):1575-9. PubMed ID: 8240434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.
    Pope JE; Bellamy N; Seibold JR; Baron M; Ellman M; Carette S; Smith CD; Chalmers IM; Hong P; O'Hanlon D; Kaminska E; Markland J; Sibley J; Catoggio L; Furst DE
    Arthritis Rheum; 2001 Jun; 44(6):1351-8. PubMed ID: 11407694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Generalized scleroderma. Treatment with immunosuppressive agents].
    Saporta L; Godeau P; Delrieu F; Delbarre F
    Nouv Presse Med; 1972 Jul; 1(29):1929-30. PubMed ID: 5053601
    [No Abstract]   [Full Text] [Related]  

  • 5. [Immediate results of long-term treatment of systemic scleroderma with leukeran].
    Olszewska Z
    Reumatologia; 1978; 16(2):259-66. PubMed ID: 358343
    [No Abstract]   [Full Text] [Related]  

  • 6. A double-blind randomized controlled trial of ketotifen versus placebo in early diffuse scleroderma.
    Gruber BL; Kaufman LD
    Arthritis Rheum; 1991 Mar; 34(3):362-6. PubMed ID: 2003858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclophosphamide versus placebo in scleroderma lung disease.
    Tashkin DP; Elashoff R; Clements PJ; Goldin J; Roth MD; Furst DE; Arriola E; Silver R; Strange C; Bolster M; Seibold JR; Riley DJ; Hsu VM; Varga J; Schraufnagel DE; Theodore A; Simms R; Wise R; Wigley F; White B; Steen V; Read C; Mayes M; Parsley E; Mubarak K; Connolly MK; Golden J; Olman M; Fessler B; Rothfield N; Metersky M;
    N Engl J Med; 2006 Jun; 354(25):2655-66. PubMed ID: 16790698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy.
    Berk PD; Goldberg JD; Silverstein MN; Weinfeld A; Donovan PB; Ellis JT; Landaw SA; Laszlo J; Najean Y; Pisciotta AV; Wasserman LR
    N Engl J Med; 1981 Feb; 304(8):441-7. PubMed ID: 7005681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial.
    Black CM; Silman AJ; Herrick AI; Denton CP; Wilson H; Newman J; Pompon L; Shi-Wen X
    Arthritis Rheum; 1999 Feb; 42(2):299-305. PubMed ID: 10025924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial.
    Seibold JR; Korn JH; Simms R; Clements PJ; Moreland LW; Mayes MD; Furst DE; Rothfield N; Steen V; Weisman M; Collier D; Wigley FM; Merkel PA; Csuka ME; Hsu V; Rocco S; Erikson M; Hannigan J; Harkonen WS; Sanders ME
    Ann Intern Med; 2000 Jun; 132(11):871-9. PubMed ID: 10836913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunosuppressive treatment of collagen diseases].
    Cruchaud A
    Ther Umsch; 1969 Dec; 26(12):697-702. PubMed ID: 5386688
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of systemic scleroderma with ketanserin. Randomized, double-blind 6-months study of 27 cases].
    Cadranel J; Blétry O; Guillevin L; Lacombe C; Fraitag B; Duloroy J; Mouthon JM; Godeau P
    Ann Med Interne (Paris); 1986; 137(3):260-3. PubMed ID: 3532900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current aspects of immunosuppressive therapy of collagen diseases].
    Marmont A; Rossi F; Bordo D
    Minerva Med; 1973 Jun; 64(46):2436-50. PubMed ID: 4723570
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunosuppressive effects of isoprinosine in man: a comparison to chlorambucil effects in multiple sclerosis.
    Pompidou A; Rancurel G; Delsaux MC; Meunier C; Telvi L; Cour V; Buge A
    Cancer Detect Prev Suppl; 1987; 1():377-83. PubMed ID: 2446758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
    Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
    Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
    Tashkin DP; Roth MD; Clements PJ; Furst DE; Khanna D; Kleerup EC; Goldin J; Arriola E; Volkmann ER; Kafaja S; Silver R; Steen V; Strange C; Wise R; Wigley F; Mayes M; Riley DJ; Hussain S; Assassi S; Hsu VM; Patel B; Phillips K; Martinez F; Golden J; Connolly MK; Varga J; Dematte J; Hinchcliff ME; Fischer A; Swigris J; Meehan R; Theodore A; Simms R; Volkov S; Schraufnagel DE; Scholand MB; Frech T; Molitor JA; Highland K; Read CA; Fritzler MJ; Kim GHJ; Tseng CH; Elashoff RM;
    Lancet Respir Med; 2016 Sep; 4(9):708-719. PubMed ID: 27469583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ketanserin in the treatment of systemic sclerosis: a double-blind controlled trial.
    Ortonne JP; Torzuoli C; Dujardin P; Fraitag B
    Br J Dermatol; 1989 Feb; 120(2):261-6. PubMed ID: 2647122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hair changes in immunosuppressive therapy].
    Kostanecki W; Mazurkiewicz W; Górkiewicz A; Zborzil J
    Z Haut Geschlechtskr; 1971 Oct; 46(19):704-8. PubMed ID: 5137252
    [No Abstract]   [Full Text] [Related]  

  • 19. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis.
    Ren S; Wang Y; Xian L; Toyama T; Jardine M; Li G; Perkovic V; Hong D
    PLoS One; 2017; 12(9):e0184398. PubMed ID: 28898290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.